Results: A total of 325 IMRT treatment verifications have been performed (315 RA), with more than 700 portal images analyzed. Although we use a quite restrictive protocol (local gamma index) the average number of points that passed the mentioned criterion has been 95.1% (range: 83.5 -99.9,std dev: 4%). The worse cases results have been found in IMRT static fields (like mantle type fields), in complex cases (non-coplanar 6 arcs treatment, very large fields even exceeding the detector size) and in RA plans with a large number of arcs in which the acquired images show a pattern of regions with large portions shielded. We use Portal Dosimetry in each IMRT plan prior to treatment due mainly to the characteristics of the detector, but it has to be used in conjunction with other dosimetric systems. On one side are the limitations of the prediction algorithm, and on the other it is difficult to establish the acceptance levels for gamma analysis results especially for RA where the whole arc is acquired in one image. Conclusions: Portal Dosimetry is being used in routine in IMRTpretreatment patient-specific verifications. For most of the cases pass rates are quite high, but another two systems are used in conjunction in order to decide the acceptability of the plan. Specific acceptance levels guidances provided by vendor would be very helpful to users. Purpose/Objective: Total body irradiation treatments are usually checked with in-vivo dosimetry measurements. In our institution we use a diodes-based in-vivo dosimetry system, composed of diodes, electrometer and software. A single failure in one of the components may make the system unusable. We aimed to evaluate Gafchromic EBT2 radiochromic film (International Specialty Products) as a backup system for diodes to perform in-vivo dosimetry for total body irradiation treatments. Materials and Methods: EBT2 films readings were compared to a Farmer 30013 chamber (PTW) and EDP-15 diodes (IBA) in a solid water phantom, in TBI conditions: 6 MV photon beam (Varian 2100 linac), 40x40 cm 2 field, SSD=315 cm, 1 cm PMMA beam spoiler. Films were located at the phantom surface, under a 1 cm bolus slab. Diodes were also at surface and ionization chamber was situated at phantom midplane (9 cm depth). Two films were irradiated each time. EBT2 films were tested for post-irradiation time influence, linearity, accuracy and reproducibility. We also measured attenuation of bolus+film and assessed the influence of interruptions during irradiation. A film inside the phantom measured a PDD curve. Red channel calibration was used to read the films. The method was clinically tested in three patients: a 2x2 cm 2 piece of film was affixed to patient's skin (at abdomen) below a 1 cm bolus slab. Film reading was converted to mid-plane dose and compared with diode readings. Results: We found that films response remains stable after around 24 h. Dose linearity was excellent in the range 10-200 cGy. PDD measurement showed a dose value at mid-plane of 79.3% of maximum dose, while PDD measured with ionization chamber showed a value of 80.4%. Film dose readings were within 3% respect to chamber dose values (mean -1.6%), except for one film (6%). Difference between film and diodes were within 4.6% (mean -3.2%), except for one film (7.5%). Film reproducibility was within 2% (10 films). Since one of the films showed a very different dose from the mean value (6%), reproducibility would drop to 1.4% if this film was not considered. No significant influence of interruption time was detected for an interruption time up to 6 min. Bolus slab and EBT2 film produced an attenuation of 2.5% at phantom mid-plane. Results from the three patients studied showed a deviation of 2.5%, 3.1% and 2.0% between EBT2 films and diodes. Conclusions: We developed a practical method to use EBT2 film as a backup system for diodes in TBI in-vivo dosimetry. Mean film dose readings differed from diodes less than 3.5%, in phantom and clinical conditions. EBT2 films are an adequate in-vivo dosimeter provided some precautions are taken: films should be read 24 h after irradiation and we recommend using at least 2 pieces of film for each location, and set up the bolus slab with film at a different position each session to diminish the attenuation effect.
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In vivo dosimetry with mosfet detectors for whole breast tomodirect treatments P. Catuzzo Purpose/Objective: TomoDirect TM (TD) is a non-rotational treatment option implemented on the TomoTherapy Hi-Art system (Accuray, Inc., Sunnyvale, CA). It stands as an alternative to conventional linac system, allowing to deliver IMRT treatments with a static gantry position. With the introduction of TD new potentialities for the treatment of the whole breast are now available. Since some protocols recommended to systematically check the absorbed dose delivered in new treatment techniques to a patients' sample implementing in-vivo dosimetry protocol, we decided to study the effectiveness of MOSFET (TN-502 RDM-H standard microMOSFET Thomson & Nielsen, Ottawa, ON Canada) as in-vivo dosimeters during TD treatment of breast cancer. Materials and Methods: The MOSFETs were calibrated against an ionization chamber type Exradin A1SL (Standard Imaging, Middleton, WI) using a modulated TD beam calculated on PMMA phantom. The entrance and exit dose calibration factors were determined in a solid water phantom positioning the MOSFET with the required hemispherical brass build-up cup. To verify the MOSFET effectiveness during in vivo dosimetry, dose measurements were performed on whole breast treatment plans created using TD two opposed tangential beams technique on an anthropomorphic Rando female thorax phantom (Phantom Laboratory, Salem, New York). Measurements were performed positioning MOSFET at the medial side on a point coincident with the red laser at 5 cm from radiopaque alignment marker and at the lateral side on the same defined reference point. This process was repeated several times to evaluate the reproducibility and accuracy of MOSFET measurements during treatment on a Tomotherapy Hi-Art unit. In vivo dosimetry was then performed on a total of 15 whole breast patients using the same procedure. Discrepancies between measured and calculated values for TD treatments have been evaluated. Results: The reproducibility of the MOSFET response is found to be better than 2.5% for the doses normally delivered to the patients. The difference between the MOSFET measured dose on Rando phantom and the planned dose at each point was less than 4%, with an average of -0.8 %± 1.7%. In vivo dose measurements show that the dose difference between MOSFET results and the TPS calculations was on average -0.7%, ranging from -4.7% to 4.8% with a standard deviation of the measurements of each patient less than 3%. Conclusions: In conclusion, MOSFET detectors are suitable for routine TD dose verification. Purpose/Objective: The aim of this study is to develop a novel doseverification method for intensity-modulated radiotherapy (IMRT) that expands upon the traditional DTA (extended DTA) by adding displacement directions to the distance difference. Materials and Methods: The extended DTA was acquired by measuring the distance between the isodose lines obtained from theTreatment Planning System (reference isodose line) and the film dosimetry (evaluation isodose line) (EDR2 Films: EastmanKodak Company;) of the prostate IMRT case. The extended DTA is the difference between the points at which the reference and evaluation isodose line intersect with a straight line after every 10° with respect to the origin. Furthermore, the distance of the difference was determined as both 'negative' and 'positive' if the evaluation isodose lines were both inside and outside the reference isodose lines, respectively. This latter assessment is useful because some reference isodose lines show low and high doses. The extended DTA was represented by 2D difference maps that use cylindrical projection. These maps show the angle in the horizontal axis, the dose in the vertical axis and the distance of difference (in millimeters) with the color scale. The extended DTA was performed by an in-house program and compared with the gamma analysis and the DTA using an OmniPro ImRT (IBA Dosimetry). The criterion value used for the gamma analysis and the DTA was 2mm3%, 2mm. DTA was 2mm3%, 2mm. The extended DTA was calculated using max dose and 100%, 97%, 95%, 93%, 90% and 80% of the isodose lines. Results: The extended DTA in the 2D difference map showed a value
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